Page last updated: 2024-10-15
cyadox
Description
cyadox: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 135412736 |
| SCHEMBL ID | 1817373 |
| SCHEMBL ID | 10793569 |
| MeSH ID | M0074764 |
Synonyms (11)
| Synonym |
|---|
| cyadox |
| acetic acid, cyano-, (2-quinoxalinylmethylene)hydrazide, n,n-dioxide |
| ciadox |
| AKOS015917705 |
| 65884-46-0 |
| SCHEMBL1817373 |
| SCHEMBL10793569 |
| DTXSID501014550 |
| 2-cyano-n-[(e)-(1,4-dioxidoquinoxaline-1,4-diium-2-yl)methylideneamino]acetamide |
| 3-{[(1-hydroxy-4-oxo-4lambda~5~-quinoxalin-2(1h)-ylidene)methyl]diazenyl}-3-oxopropanenitrile |
| DTXSID10867186 |
Research Excerpts
Overview
Cyadox (CYX) is a synthetic antibacterial agent of quinoxaline with much lower toxic effects. Cyadox is an antibiotic drug and has the potential to be used as a feedstuff additive in promoting the growth of animals.
Toxicity
The relatively new QdNOs, cyadox (CYA), mequindox (MEQ), quinocetone (QCT) and their metabolites, were selected for elucidation of their toxic mechanisms in H295R cells. However, the pharmacological and toxicological bioactive molecules of Cyadox remain unclear.
| Excerpt | Reference |
|---|---|
| " The relatively new QdNOs, cyadox (CYA), mequindox (MEQ), quinocetone (QCT) and their metabolites, were selected for elucidation of their toxic mechanisms in H295R cells." | ( High risk of adrenal toxicity of N1-desoxy quinoxaline 1,4-dioxide derivatives and the protection of oligomeric proanthocyanidins (OPC) in the inhibition of the expression of aldosterone synthetase in H295R cells. Chen, D; Cheng, G; Dai, M; Guo, P; Ihsan, A; Liu, Z; Luo, X; Wang, X; Yang, C; Yuan, Z, 2016) |
| " However, the pharmacological and toxicological bioactive molecules of cyadox and the molecular mechanism of its pharmacological and toxic actions remain unclear." | ( N-O Reduction and ROS-Mediated AKT/FOXO1 and AKT/P53 Pathways Are Involved in Growth Promotion and Cytotoxicity of Cyadox. Dai, M; Lei, Z; Liu, Q; Liu, S; Sun, Q; Wang, X; Yu, H; Yuan, Z; Zhou, K, 2018) |
Pharmacokinetics
| Excerpt | Reference |
|---|---|
| "Physiologically based pharmacokinetic (PBPK) models are powerful tools to predict tissue distribution and depletion of veterinary drugs in food animals." | ( Estimation of residue depletion of cyadox and its marker residue in edible tissues of pigs using physiologically based pharmacokinetic modelling. Gehring, R; Huang, L; Lin, Z; Riviere, JE; Yuan, Z; Zhou, X; Zhu, M, 2015) |
| " The terminal half-life and mean resident time of Cyx nanosuspension had also increased compared to normal Cyx suspension." | ( Preparation, characterization and pharmacokinetics of cyadox nanosuspension. Chen, D; Huang, L; Jiang, L; Liu, Z; Pan, Y; Sattar, A; Tao, Y; Xie, S; Yuan, Z, 2017) |
Compound-Compound Interactions
| Excerpt | Reference |
|---|---|
| " The metabolites of CYX were identified using high-performance liquid chromatography combined with ion trap/time-of-flight mass spectrometry (LC/MS-ITTOF)." | ( Metabolism of cyadox by the intestinal mucosa microsomes and gut flora of swine, and identification of metabolites by high-performance liquid chromatography combined with ion trap/time-of-flight mass spectrometry. Chen, D; Huang, L; Liu, Z; Pan, Y; Peng, D; Tao, Y; Wang, X; Wang, Y; Xu, N; Yuan, Zh, 2011) |
Bioavailability
| Excerpt | Reference |
|---|---|
| "An increase in number of newly developed synthetic drugs displays bioavailability constraints because of poor water solubility." | ( Preparation, characterization and pharmacokinetics of cyadox nanosuspension. Chen, D; Huang, L; Jiang, L; Liu, Z; Pan, Y; Sattar, A; Tao, Y; Xie, S; Yuan, Z, 2017) |
Dosage Studied
Cyadox groups (200, 50 and 10 mg/kg) with irradiation had erythema and oedema of auricular skin. Effect of cyadox was very low even at the highest dosage tested.
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (56)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (17.86) | 18.7374 |
| 1990's | 3 (5.36) | 18.2507 |
| 2000's | 8 (14.29) | 29.6817 |
| 2010's | 30 (53.57) | 24.3611 |
| 2020's | 5 (8.93) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (5.17%) | 5.53% |
| Reviews | 1 (1.72%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 54 (93.10%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||